Last $22.07 USD
Change Today +0.15 / 0.68%
Volume 371.0K
CBM On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

cambrex corp (CBM) Snapshot

Open
$21.87
Previous Close
$21.92
Day High
$22.25
Day Low
$21.66
52 Week High
08/1/14 - $23.88
52 Week Low
09/6/13 - $12.56
Market Cap
677.1M
Average Volume 10 Days
206.2K
EPS TTM
$0.85
Shares Outstanding
30.7M
EX-Date
05/4/07
P/E TM
25.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for CAMBREX CORP (CBM)

cambrex corp (CBM) Related Bloomberg News

View More Bloomberg News

cambrex corp (CBM) Related Businessweek News

No Related Businessweek News Found

cambrex corp (CBM) Details

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products consist of active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products. The company serves generic drug companies, and companies that discover and commercialize new small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

cambrex corp (CBM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $533.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $400.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $412.5K
Managing Director of Cambrex Profarmaco Milan...
Total Annual Compensation: $338.7K
Compensation as of Fiscal Year 2013.

cambrex corp (CBM) Key Developments

Cambrex Corporation. Announces Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revises Earnings Guidance for 2014

Cambrex Corporation. announced earnings results for the second quarter and six months ended June 30, 2014. For the period, the company reported net sales of $97,347,000 against $61,563,000 a year ago. Net revenues were $97,893,000 against $62,803,000 a year ago. Operating profit was $15,224,000 against $5,864,000 a year ago. Income before income taxes was $10,412,000 against $4,670,000 a year ago. Income from continuing operations was $19,827,000 or $0.63 per diluted share against $3,136,000 or $0.10 per diluted share a year ago. Net income was $19,667,000 or $0.63 per diluted share against $2,274,000 or $0.07 per diluted share a year ago. EBITDA was $21,190,000 against $11,417,000 a year ago. Adjusted income from continuing operations was $10,963,000 or $0.35 per diluted share against $4,132,000 or $0.13 per diluted share a year ago. Capital expenditures were $6.0 million compared to $13.1 million in the same period last year. For the six months, the company reported net sales of $162,990,000 against $135,981,000 a year ago. Net revenues were $163,998,000 against $137,688,000 a year ago. Operating profit was $17,694,000 against $21,995,000 a year ago. Income before income taxes was $12,032,000 against $19,857,000 a year ago. Income from continuing operations was $20,993,000 or $0.67 per diluted share against $14,561,000 or $0.47 per diluted share a year ago. Net income was $20,649,000 or $0.66 per diluted share against $13,442,000 or $0.44 per diluted share a year ago. Adjusted operating profit was $17,694,000 against $17,315,000 a year ago. Adjusted EBITDA was $29,543,000 against $28,201,000 a year ago. Adjusted income from continuing operations was $12,925,000 or $0.41 per diluted share against $12,087,000 or $0.39 per diluted share a year ago. The company revised earnings guidance for 2014. For 2014, the company’s adjusted EBITDA is to be in the range of $74 - $78 million from $70 - $76 million as expected previously. Adjusted income from continuing operations per share is to be in the range of $1.07 - $1.15 from $0.99 - $1.10 as expected previously. Capital expenditures are to be in the range of $35 - $39 million from $35 - $39 million as expected previously. Depreciation is to be in the range of $25 - $27 million from $25 - $27 million as expected previously. Effective tax rate is to be in the range of 33% - 36% from 33% - 37% as expected previously. Consistent with prior guidance for the full year 2014, these financial expectations are for continuing operations and exclude the impact of any potential acquisitions, restructuring activities and outcomes of tax disputes and do not reflect Zenara's results. Sales expectations exclude the impact of foreign currency. The company continues to expect Zenara to generate low single digit millions in revenues and a small EBITDA loss in 2014.

Cambrex Mulls Acquisitions

Cambrex Corporation. (NYSE:CBM) is looking for acquisitions. Regarding acquisitions, President and Chief Executive Officer, Steve Klosk said, “We had more activity than usual in the first half of the year, and especially the second quarter, looking at various M&A opportunities where unfortunately end up hiring a fair number of lawyers, accountants and outside experts to kind of evaluate these opportunities.”

Cambrex Corporation. to Report Q2, 2014 Results on Aug 01, 2014

Cambrex Corporation. announced that they will report Q2, 2014 results on Aug 01, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBM:US $22.07 USD +0.15

CBM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBM.
View Industry Companies
 

Industry Analysis

CBM

Industry Average

Valuation CBM Industry Range
No financial data is available for CBM.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAMBREX CORP, please visit www.cambrex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.